Invest in the next big thing.
Find us on the CSE: OMND
Corporate Overview
Optimind Pharma is an emerging provider of psychedelic therapies for the masses. We help people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities so that they can heal and live life fully. We are also partnered with developers of psilocybin-associated treatments and products to further expand our treatment and program offerings.
Recent News
Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy
Optimind looks to accelerate the adoption of the MindSetting(TM) TRIP Protocol for ketamine-assisted therapy and other psychedelic enhanced psychotherapy modalities. Toronto, Ontario--(Newsfile Corp. - September 20, 2022) - Optimind Pharma Corp. (CSE: OMND)...
Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari Pharma
Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari PharmaManitari Pharma received approval to begin construction of Security Level 3 safe + grow rooms Manitari Pharma is one step closer to obtaining Controlled Substances...
Optimind Pharma Commences Trading on the CSE Under Ticker Symbol OMND
Optimind Pharma Commences Trading on the CSE Under Ticker Symbol OMNDTORONTO – Optimind Pharma Corp. (CSE:OMND (“Optimind” or the “Company”) today announced its commencement of trading on the CSE (Canadian Securities Exchange) under ticker symbol “OMND”. Optimind...
Optimind Pharma Announces Closing of Reverse Takeover Transaction
Optimind Pharma Announces Closing of Reverse Takeover TransactionToronto, Ontario--(Newsfile Corp. - July 29, 2022) - Optimind Pharma Corp. ("Optimind" or the "Company") announces the successful closing of its previously announced reverse takeover ("RTO") of Loon...